Keywords: بقا بدون پیشرفت; BM; brain metastasis; AE; adverse event; CI; confidence interval; CTLA4; cytotoxic T-lymphocyte antigen-4; CT; computed-tomography; GPA; Graded Prognostic Assessment score; IORR; intracerebral objective response rate; IQR; interquartile range; NSCLC; nonâ
مقالات ISI بقا بدون پیشرفت (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: بقا بدون پیشرفت; Dacarbazine; Ki-67 index; Neuroendocrine carcinoma; Neuroendocrine tumors; Overall survival; Progression-free survival;
Keywords: بقا بدون پیشرفت; CT; chemotherapy; EBRT; external beam radiotherapy; EEC; endometrial endometrioid carcinoma; HGSOC; high-grade serous ovarian cancer; HR; hazard ratio; IQR; interquartile range; OS; overall survival; PbCT; platinum-based chemotherapy; PFS; progression-fre
Keywords: بقا بدون پیشرفت; kidney; carcinoma; renal cell; neoplasm invasiveness; fascia; mortality; MVI; microvascular invasion; OS; overall survival; PFS; progression-free survival; PS; pseudocapsule; RCC; renal cell carcinoma;
Keywords: بقا بدون پیشرفت; Glioblastoma; Long-term survival; 10â¯years; Progression-free survival;
Keywords: بقا بدون پیشرفت; AUC; area under the curve; CE; cost effectiveness; CEAC; cost-effectiveness acceptability curve; CI; confidence interval; DMSIC; Drug and Medical Supply Information Center; DRG; diagnosis-related group; DSA; deterministic sensitivity analysis; EGFR; epide
Keywords: بقا بدون پیشرفت; Cisplatin; Gemcitabine; Metastatic collecting duct carcinoma; Progression-free survival; Sorafenib;
Keywords: بقا بدون پیشرفت; Ovarian cancer; Complete gross resection; Primary debulking surgery; Surgical paradigm; Progression-free survival; Overall survival;
Keywords: بقا بدون پیشرفت; Urothelial cancer; Surrogacy; Randomized controlled trials; Progression-free survival;
Keywords: بقا بدون پیشرفت; metastatic breast cancer; MBC; lobaplatin and gemcitabine; GL; lobaplatin and vinorelbine; NL; cisplatin and gemcitabine; GP; cisplatin and vinorelbine; NP; progression-free survival; PFS; overall survival; OS; response rate; RR; platinum-based compounds;
Keywords: بقا بدون پیشرفت; Cabazitaxel; Metastatic castration-resistant prostate cancer; Rechallenge; Overall survival; Progression-free survival; Taxanes; Safety;
Keywords: بقا بدون پیشرفت; Advanced breast cancer; PI3K inhibitor; Progression-free survival; Toxicity; Systematic review; Meta-analysis;
Keywords: بقا بدون پیشرفت; DOT; Overall survival; Progression-free survival; RRMM; Time to next therapy;
Keywords: بقا بدون پیشرفت; urinary bladder neoplasms; urothelium; urologic neoplasms; drug therapy; combination; mortality; BCa; bladder cancer; EORTC; European Organization for the Research and Treatment of Cancer; GC; gemcitabine and cisplatin; HD; high dose; MCAVI; methotrexate,
Keywords: بقا بدون پیشرفت; urinary bladder neoplasms; neoplasm invasiveness; neoplasm recurrence; local; BCG vaccine; mortality; BCG; bacillus Calmette-Guérin; CIS; carcinoma in situ; CR; complete response; DSS; disease specific survival; MIBC; muscle invasive bladder cancer; NMIB
Keywords: بقا بدون پیشرفت; PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
Keywords: بقا بدون پیشرفت; BB; bevacizumab-bevacizumab; BP; bevacizumab followed by panitumumab; CA9; carbonic anhydrase 9; CRC; colorectal cancer; DEGs; differentially expressed genes; EGFR; epidermal growth factor receptor; EPHA2; ephrin type-A receptor 2; FASN; fatty acid syntha
Keywords: بقا بدون پیشرفت; ABC; activated-B Cell; BTK; Bruton's tyrosine kinase; CNS; Central nervous system; CLL; chronic lymphocytic leukemia; DLBCL; Diffuse Large B-cell lymphoma; DAB; diaminobenzidin; DNMT; DNA methyltransferase; GO; gene ontology; GCB; germinal center cell lik
Keywords: بقا بدون پیشرفت; biomarker; cancer outcome; cutaneous adverse event; cutaneous toxicity; oncodermatology; prognostic marker; survival; HFS; hand foot syndrome; HFSR; hand-foot skin reaction; HR; hazard ratio; irAE; immune-related adverse effect; NSCLC; non-small cell
Keywords: بقا بدون پیشرفت; Long-term response; Metastatic; Objective response rate; Predictors; Progression-free survival;
Keywords: بقا بدون پیشرفت; Brain neoplasm; Clinical trials; Glioblastoma; Immunotherapeutic; Immunotherapy; Vaccine; APC; Antigen-presenting cell; APVAC; Actively personalized vaccination; BBB; Blood-brain barrier; CMV; Cytomegalovirus; CNS; Central nervous system; CSF; Cerebrosp
Keywords: بقا بدون پیشرفت; AIHA; autoimmune hemolytic anemia; B2M; β2-microglobulin; BR; bendamustine and rituximab; BTK; Bruton tyrosine kinase; CLL; chronic lymphocytic leukemia; CR; complete remission; FCR; fludarabine; cyclophosphamide; and rituximab; FISH; fluorescence in sit
Keywords: بقا بدون پیشرفت; AI; aromatase inhibitor; ASCO; American Society of Clinical Oncology; CDK4/6; cyclin-dependent kinase 4/6; DCIS; ductal carcinoma in situ; DFS; disease-free survival; ER; estrogen receptor; FDA; Food and Drug Administration; HER2; human epidermal growth f
Keywords: بقا بدون پیشرفت; Atypical pituitary adenoma; Clinically aggressive adenoma; Ki-67 index; Invasion; Progression-free survival;
Keywords: بقا بدون پیشرفت; Platelet-to-lymphocyte ratio (PLR); Prognosis; Advanced cancer; Meta-analysis; PLR; platelet-to-lymphocyte ratio; OS; overall survival; PFS; progression-free survival; DFS; disease-free survival; CSS; cancer-specific survival; MeSH; Medical Subject Headin
Keywords: بقا بدون پیشرفت; Immunoassay; Serum biomarker; Cancer; Follow-up; Prognosis; Histotype; HE4; human epididymis protein 4; OC; ovarian cancer; CA125; carbohydrate antigen 125; HR; hazard ratio; PFS; progression-free survival; NCCN; National Comprehensive Cancer Network; GCI
Keywords: بقا بدون پیشرفت; APC; Antigen presenting cells; CIMP; CpG island methylator phenotype; CIN; chromosomal instability; CRC; colorectal cancer; CTLA-4; cytotoxic T lymphocyte-associated protein 4; DAMPs; danger-associated molecular patterns; FDA; US Food and Drug Administr
Keywords: بقا بدون پیشرفت; 5FU; 5-fluorouracil; 95%CI; 95% confidence interval; AA; amino acid; AFP; alpha fetoprotein; AML; actue myeloid leukemia; Ang2; angiopoietin 2; ATP; adenosine triphosphate; BCLC; Barcelona-Clinic Liver Cancer classification; BSC; best supportive care; CAP
Keywords: بقا بدون پیشرفت; AE; adverse event; ADR; adverse drug reaction; ANC; absolute neutrophil count; CI; confidence interval; CR; complete remission; CTCAE; common terminology criteria for adverse events; DEX; dexamethasone; ECOG; eastern cooperative oncology group; eCRF; elec
Keywords: بقا بدون پیشرفت; ADT; androgen deprivation therapy; AE; adverse event; CRPC; castration-resistant prostate cancer; LHRH; luteinizing hormone-releasing hormone; mCRPC; metastatic CRPC; MFS; metastase-free survival; nmCRPC; non-metastatic CRPC; PFS; progression-free surviva
Keywords: بقا بدون پیشرفت; Intracranial meningioma; Long-term follow-up; Meningioma surgery; Non-skull base meningiomas; Progression-free survival; Recurrence; Skull base meningiomas; Tumor progression rate; EOR; Extent of resection; GTR; Gross total resection; IDM; Incidentally
Keywords: بقا بدون پیشرفت; A; astrocytoma; AA; anaplastic astrocytoma; AO; anaplastic oligodendroglioma; AOA; anaplastic oligoastrocytoma; EGFR; epidermal growth factor receptor; FISH; fluorescence in situ hybridization; MGMT; O6-methylguanine-DNA methyltransferase; MMP9; matrix me
Keywords: بقا بدون پیشرفت; Androgen deprivation therapy; Castration-resistant prostate cancer (CRPC); Overall survival; Progression-free survival; Serum testosterone;
Keywords: بقا بدون پیشرفت; DLBCL; diffuse large B-cell lymphoma; R-CHOP; rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; NHL; non-Hodgkin lymphoma; GEP; gene expression profiling; COO; cell-of-origin; GCB; germinal center B-cell; ABC; activated B-cell; PMBL;
Keywords: بقا بدون پیشرفت; PC; prostate cancer; mPC; metastatic prostate cancer; ADT; androgen deprivation therapy; CRPC; castration resistant prostate cancer; mCRPC; metastatic CRPC; SNP; single nucleotide polymorphism; CNV; copy number variation; AR; androgen receptor; CTC; circu
Keywords: بقا بدون پیشرفت; Chemoprevention; Drug; Insulin Resistance; Pancreas; AMPK; adenosine monophosphate-activated kinase; CI; confidence interval; HR; hazard ratio; mTOR; mechanistic target of rapamycin; OS; overall survival; PFS; progression-free survival; pNET; pancreatic n
Keywords: بقا بدون پیشرفت; uPA; urokinase plasminogen activator; PAI-1; plasminogen activator inhibitor 1; ctDNA; circulating tumor DNA; CTC; circulating tumor cells; PFS; progression-free survival; pCR; pathological complete response; SNVs; single nucleotide variants; CNVs; copy n
Keywords: بقا بدون پیشرفت; Oxysterols; Cancer; Polymorphism; Risk; Genetics; Cholesterol; 25(OH)D; 25-hydroxyvitamin D; ABC; ATP-binding cassette; AEBS; antiestrogen-binding site; BC; breast cancer; BCR; biochemical recurrence; CETP; cholesteryl ester transfer protein; CH25H; chole
Keywords: بقا بدون پیشرفت; NSCLC; non small-cell lung cancer; EGFR; epidermal growth factor receptor; TKI; tyrosine kinase inhibitor; PFS; progression-free survival; ECOG; Eastern Cooperative Oncology Group; RECIST; Response Evaluation Criteria in Solid Tumors; ECG; electrocardiogr
Keywords: بقا بدون پیشرفت; Cytogenetic; Meningiomas; Simpson grade; WHO grade; MRI; Magnetic resonance imaging; PFS; Progression-free survival; SFRT; Stereotactic fractionated radiotherapy; WHO; World Health Organization;
Keywords: بقا بدون پیشرفت; Low dose; Metronomic chemotherapy; Metastatic colorectal cancer; CRC; colorectal cancer; mCRC; metastatic colorectal cancer; MTD; maximal tolerated dose; PFS; progression-free survival; OS; overall survival; TSP-1; thrombospondin-1;
Keywords: بقا بدون پیشرفت; Abiraterone acetate; mCRPC; Progression-free survival; PSA decline; PSA flare;
Keywords: بقا بدون پیشرفت; IDC; invasive ductal carcinoma; IL-35; interleukin-35; Tregs; regulatory T cells; TILs; tumor-infiltrating lymphocytes; EBI3; Epstein-Barr Virus (EBV)-induced gene 3; Bregs; regulatory B cells; PFS; progression-free survival; OS; overall survival; ER; est
Keywords: بقا بدون پیشرفت; Head and neck cancer; Pharyngeal cancer; Extracapsular extension; Human papillomavirus; P16-positive; Distant metastasis; Progression-free survival; Adjuvant radiotherapy; Adjuvant chemotherapy;
Keywords: بقا بدون پیشرفت; Gastric cancer; Elderly; Chemotherapy; Randomized controlled trial; AGC; advanced gastric cancer; 5-FU; 5-fluorouracil; OS; overall survival; RCT; randomized controlled trial; PFS; progression-free survival; RR; response rate; QoL; quality of life; KG-7;
Keywords: بقا بدون پیشرفت; Oligorecurrent prostate cancer; Lymph node metastasis; Stereotactic body radiotherapy; Local control; Progression-free survival; Androgen-deprivation free survival;
Keywords: بقا بدون پیشرفت; Chemotherapy; Gliosarcoma; MGMT; Prognosis; Radiotherapy; GBM; Glioblastoma; KPS; Karnofsky Performance Scale; MGMT; Methylguanine DNA methyl transferase; OS; Overall survival; PFS; Progression-free survival;
Keywords: بقا بدون پیشرفت; Splenectomy; SMZL; Complications; Survival; Outcomes; Surgery; SMZL; splenic marginal zone lymphoma; OS; overall survival; PFS; progression-free survival; ASA; American Society of Anesthesiologists; IQR; Interquartile Range; OR; Odds Ratio; IIL-score; Int
Keywords: بقا بدون پیشرفت; CAF; cancer associated fibroblast; GRP78; glucose-regulated protein 78; DC; dendritic cell; NK; natural killer cell; MDSC; myeloid-derived suppressor cell; TIL; tumor-infiltration lymphocyte; TAM; tumor-associated macrophage; NSCLC; non-small cell lung ca
Keywords: بقا بدون پیشرفت; SCLC; small cell lung cancer; ILD; interstitial lung disease; NSCLC; non-small cell lung cancer; TTF-1; thyroid transcription factor-1; UIP; usual interstitial pneumonia; AE; acute exacerbation; PFS; progression-free survival; OS; overall survival; PS; pe